With Cancer Vaccines in Play, Will Investors Continue to Buy-In?
M.E. Garza submits:
BioSante Pharmaceuticals (BPAX) announced Monday that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA, but will that news be enough to get investors to buy-in and hold on to shares? In May of last year, the company announced that the treatment of prostate cancer has been reinitiated and that manufacturing of new GVAX Prostate was in process. Regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation had been taken at that time, and prostate cancer patients were expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010.This week the company said that manufacturing of new GVAX Prostate is complete, and planning for a Phase II clinical trial at the Johns Hopkins Kimmel Cancer Center is still underway.While it is not immediatelyComplete Story »